Enrollment of the first patient for T-1301 Phase I clinical trial was achieved in August, 2022.
T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient recruitment, the enrollment of the first patient (First-patient-in, FPI) was accomplished in August, 2022. Meanwhile, patient recruitment is ongoing. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting …